Next Article in Journal
The Effect of the Particle Size Reduction on the Biorelevant Solubility and Dissolution of Poorly Soluble Drugs with Different Acid-Base Character
Previous Article in Journal
Microneedle-Mediated Transdermal Delivery of Biopharmaceuticals
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 15
Issue 1
10.3390/pharmaceutics15010279
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Pharmaceutics 2022, 14(8), 1620.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Zare et al. Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics. Pharmaceutics 2022, 14, 1620

by
Mina Zare
1,2,†,
Rakesh Pemmada
3,†,
Maya Madhavan
4,*,
Aswathy Shailaja
5,
Seeram Ramakrishna
1,
Sumodan Padikkala Kandiyil
6,
James M. Donahue
7 and
Vinoy Thomas
3,8,*
1
Center for Nanotechnology and Sustainability, Department of Mechanical Engineering, National University of Singapore, Singapore 117581, Singapore
2
Department of Food and Nutrition, University of Helsinki, 00014 Helsinki, Finland
3
Departments of Materials Science and Engineering, Biomedical Engineering, University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA
4
Department of Biochemistry, Government College for Women, Thiruvananthapuram 695014, India
5
Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA
6
Post Graduate Department of Zoology, Government College, Madappally 673102, India
7
School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
8
Center for Nanoscale Materials and Biointegration (CNMB), Center for Clinical and Translational Science (CCTS), University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceutics 2023, 15(1), 279; https://doi.org/10.3390/pharmaceutics15010279
Submission received: 7 November 2022 / Accepted: 21 November 2022 / Published: 13 January 2023
Browse Figures
Versions Notes

Enhancement in Figure:

In the original publication [1], the figures were not sharp enough. The enhanced Figure 1, Figure 3, Figure 4, Figure 5, and Figure 7 appear below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Zare, M.; Pemmada, R.; Madhavan, M.; Shailaja, A.; Ramakrishna, S.; Kandiyil, S.P.; Donahue, J.M.; Thomas, V. Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics. Pharmaceutics 2022, 14, 1620. [Google Scholar] [CrossRef]
Pharmaceutics 15 00279 g001 550
Figure 1. Schematic representation of mechanism of gene silencing by miRNAs and siRNAs. Adapted and modified from [12] under the Creative Commons license.
Figure 1. Schematic representation of mechanism of gene silencing by miRNAs and siRNAs. Adapted and modified from [12] under the Creative Commons license.
Pharmaceutics 15 00279 g001
Pharmaceutics 15 00279 g003 550
Figure 3. Exosomal ncRNA-related mechanisms implicated in CRC drug resistance. CAFs: cancer-associated fibroblasts; ncRNAs: noncoding RNAs; miRNA: microRNA; circRNA: circular RNA; lncRNA: long noncoding RNA. Adapted and modified from [75] under the Creative Commons license.
Figure 3. Exosomal ncRNA-related mechanisms implicated in CRC drug resistance. CAFs: cancer-associated fibroblasts; ncRNAs: noncoding RNAs; miRNA: microRNA; circRNA: circular RNA; lncRNA: long noncoding RNA. Adapted and modified from [75] under the Creative Commons license.
Pharmaceutics 15 00279 g003
Pharmaceutics 15 00279 g004 550
Figure 4. Liposome-based carriers are sphere-shaped vesicles made of synthetic or natural phospholipids. Surface-modifier and -targeting groups can be conjugated to the outer surface. Phospholipids naturally form a bilayer upon aqueous dispersion, with the non-polar tails facing one other and the polar heads facing towards the aqueous phase. Hydrophilic molecules and RNAs are incorporated into the resulting inner core, while hydrophobic molecules are encapsulated in the lipid bilayer. Adapted and modified from [81] under the Creative Commons license.
Figure 4. Liposome-based carriers are sphere-shaped vesicles made of synthetic or natural phospholipids. Surface-modifier and -targeting groups can be conjugated to the outer surface. Phospholipids naturally form a bilayer upon aqueous dispersion, with the non-polar tails facing one other and the polar heads facing towards the aqueous phase. Hydrophilic molecules and RNAs are incorporated into the resulting inner core, while hydrophobic molecules are encapsulated in the lipid bilayer. Adapted and modified from [81] under the Creative Commons license.
Pharmaceutics 15 00279 g004
Pharmaceutics 15 00279 g005 550
Figure 5. Illustration of dendritic molecular structures with a central core, repeating branches, and terminal reactive functional groups. They can be classified as polymers and hyperbranched polymers with convergent and divergent architectures, depending on their molecular nature weight. Their nanostructure provides dendrimer–drug conjugation via different interactions such as electrostatic and hydrophobic/hydrogen bonds or the capacity for drug encapsulation within the central cavity and/or between the dendrons (branches). Adapted and modified from [87] under the Creative Commons license.
Figure 5. Illustration of dendritic molecular structures with a central core, repeating branches, and terminal reactive functional groups. They can be classified as polymers and hyperbranched polymers with convergent and divergent architectures, depending on their molecular nature weight. Their nanostructure provides dendrimer–drug conjugation via different interactions such as electrostatic and hydrophobic/hydrogen bonds or the capacity for drug encapsulation within the central cavity and/or between the dendrons (branches). Adapted and modified from [87] under the Creative Commons license.
Pharmaceutics 15 00279 g005
Pharmaceutics 15 00279 g007 550
Figure 7. Illustration of a bilayer lipid-based nanocarrier with encapsulated drugs in the core; the self-assembled supramolecular architecture is shown. The solid lipid matrix encapsulates bioactive components, particularly lipophilic molecules, and releases them gradually over time. Lipid polymer nanoparticles typically have spherical particles and sizes in the range of 10 to 1000 nm. There are several forms of lipid-based nanocarriers (liposomes and niosomes) reported in reference [81] for drug delivery.
Figure 7. Illustration of a bilayer lipid-based nanocarrier with encapsulated drugs in the core; the self-assembled supramolecular architecture is shown. The solid lipid matrix encapsulates bioactive components, particularly lipophilic molecules, and releases them gradually over time. Lipid polymer nanoparticles typically have spherical particles and sizes in the range of 10 to 1000 nm. There are several forms of lipid-based nanocarriers (liposomes and niosomes) reported in reference [81] for drug delivery.
Pharmaceutics 15 00279 g007
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zare, M.; Pemmada, R.; Madhavan, M.; Shailaja, A.; Ramakrishna, S.; Kandiyil, S.P.; Donahue, J.M.; Thomas, V. Correction: Zare et al. Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics. Pharmaceutics 2022, 14, 1620. Pharmaceutics 2023, 15, 279. https://doi.org/10.3390/pharmaceutics15010279

AMA Style

Zare M, Pemmada R, Madhavan M, Shailaja A, Ramakrishna S, Kandiyil SP, Donahue JM, Thomas V. Correction: Zare et al. Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics. Pharmaceutics 2022, 14, 1620. Pharmaceutics. 2023; 15(1):279. https://doi.org/10.3390/pharmaceutics15010279

Chicago/Turabian Style

Zare, Mina, Rakesh Pemmada, Maya Madhavan, Aswathy Shailaja, Seeram Ramakrishna, Sumodan Padikkala Kandiyil, James M. Donahue, and Vinoy Thomas. 2023. "Correction: Zare et al. Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics. Pharmaceutics 2022, 14, 1620" Pharmaceutics 15, no. 1: 279. https://doi.org/10.3390/pharmaceutics15010279

APA Style

Zare, M., Pemmada, R., Madhavan, M., Shailaja, A., Ramakrishna, S., Kandiyil, S. P., Donahue, J. M., & Thomas, V. (2023). Correction: Zare et al. Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics. Pharmaceutics 2022, 14, 1620. Pharmaceutics, 15(1), 279. https://doi.org/10.3390/pharmaceutics15010279

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop